0001209191-23-001342.txt : 20230104
0001209191-23-001342.hdr.sgml : 20230104
20230104182448
ACCESSION NUMBER: 0001209191-23-001342
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221230
FILED AS OF DATE: 20230104
DATE AS OF CHANGE: 20230104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mancini Marianna
CENTRAL INDEX KEY: 0001838112
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37355
FILM NUMBER: 23508820
MAIL ADDRESS:
STREET 1: C/O VIKING THERAPEUTICS, INC.
STREET 2: 12340 EL CAMINO REAL, STE 250
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viking Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607678
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 461073877
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-704-4660
MAIL ADDRESS:
STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-30
0
0001607678
Viking Therapeutics, Inc.
VKTX
0001838112
Mancini Marianna
C/O VIKING THERAPEUTICS, INC.
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO
CA
92121
0
1
0
0
Chief Operating Officer
Common Stock, par value $0.00001 per share
2022-12-30
4
A
0
23500
0.00
A
273306
D
Common Stock, par value $0.00001 per share
2022-12-30
4
F
0
12773
9.40
D
260533
D
Common Stock, par value $0.00001 per share
2023-01-03
4
A
0
90667
0.00
A
351200
D
Common Stock, par value $0.00001 per share
2023-01-03
4
F
0
18854
8.52
D
332346
D
Common Stock, par value $0.00001 per share
2023-01-04
4
F
0
13994
8.42
D
318352
D
Stock Option (Right to Buy)
8.52
2023-01-03
4
A
0
204000
0.00
A
2024-01-03
2033-01-03
Common Stock
204000
204000
D
The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2019, 66.67% of which vested on December 30, 2022 upon the achievement of two non-financial performance goals and a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on December 30, 2022 upon the achievement of a non-financial performance goal.
Includes 4,545 shares acquired on May 20, 2022 and 6,566 shares acquired on November 18, 2022 pursuant to the Issuer's 2014 Employee Stock Purchase Plan
These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units.
Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units.
25% of the shares subject to the option will vest on each anniversary of the grant date.
/s/ Michael Morneau, as Attorney-in-Fact
2023-01-04